PR94196

HURDEN, Switzerland, Jan 21, 2022 /PRNewswire=KYODO JBN/ --

IDEOGEN GROUP, Managed Access division, takes over Special Access Program for

BELEODAQ (R) (belinostat) in Europe, Middle East, North Africa, Russia, and CIS.

BELEODAQ (R) is a prescription medicine used to treat patients with a rare form

of blood cancer called peripheral T-cell lymphoma (PTCL) that relapsed or does

not respond to previous treatment. PTCL is a group of rare and aggressive

non-Hodgkin lymphomas (NHL), a malignant lymphoproliferative disorder. PTCL

accounts for approximately 10%-15% of all NHL cases.

BELEODAQ (R) (belinostat) is the only Histone Deacetylase Inhibitor (‘HDAC

inhibitor’) globally to treat refractory/relapsed PTCL. The product received

accelerated approval by the US Food and Drug Administration (‘FDA’) due to this

rare disease’s high unmet medical need.

Murat Göker, Chief Commercial Officer at Ideogen Group, commented: “Our modus

operandi is to serve the unmet medical needs of patients at the Speed of Life.

As the trusted partner, we service access for patients globally affected by

underserved diseases. Our Special Access Programs allow physicians access to

medicines like BELEODAQ (R) (belinostat) for special circumstances of

individual patients when alternative treatment options are required.

“We are privileged to be the exclusive fulfilment partner representing BELEODAQ

(R) for immediate availability across many territories*. Due to the

time-sensitive disease state of the relapsed/refractory PTCL patient, BELEODAQ

(R)  is  warehoused in the EU and available for delivery to any ordering

pharmacist or physician within continental Europe with rapid deployment,”

states Mehmet Göker, Chief Operations Officer.

Healthcare professionals can obtain details about the BELEODAQ® Special Access

Program by calling an Ideogen representative at +800 22 44 77 00 or emailing

healthcare@Ideogen.com.

About IDEOGEN: We focus on commercializing specialty medicines with challenging

and evolving healthcare dynamics. With the operational infrastructure and

know-how to handle activities from unlicensed through licensed medicines,

Ideogen sustains a strong network of professionals and caretakers, nurturing

sound medical alliances for the benefit of patients.

Our portfolio focuses on medications that require expertise in solving

challenging Regulatory, Market Access, Quality, PV, and fulfilment requirements

for specialized disease segments. From initial inquiry through timely delivery,

we are reachable 24/7 internationally.

For more information, also visit www.ideogen.com

*Exclusive Coverage of Territories: Albania, Algeria, Armenia, Austria,

Bahrain, Belgium, Bosnia, Bulgaria, Croatia, Cyprus, Czech-Republic, Denmark,

Djibouti, Egypt, Estonia, Finland, France, Georgia, Germany, Greece, Hungary,

Iceland, Iran, Iraq, Ireland, Israel, Italy, Jordan, Kazakhstan, Kirgizstan,

Kuwait, Latvia, Lebanon, Libya, Liechtenstein, Lithuania, Luxembourg,

Macedonia, Malta, Moldova, Monaco, Montenegro, Morocco, Netherlands, Norway,

Oman, Palestine, Poland, Portugal, Qatar, Romania, Russia, Saudi Arabia,

Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Syria, Turkey, Tunisia,

Ukraine, UK, Uzbekistan, UAE, and Yemen.

Logo - https://mma.prnewswire.com/media/1730926/Ideogen_Logo.jpg

For Media Relations please contact: info@idoegen.com;

bettina.wassmann@ideogen.com; phone: +41 43 311 5252

Source: IDEOGEN AG